Anika Therapeutics, Inc.
ANIK
$14.01
-$0.68-4.63%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.03% | -7.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.03% | -7.56% | |||
| Cost of Revenue | -65.51% | 156.34% | |||
| Gross Profit | 1,131.32% | -94.74% | |||
| SG&A Expenses | -40.75% | -3.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -51.78% | 52.46% | |||
| Operating Income | 99.60% | -15,575.78% | |||
| Income Before Tax | 100.14% | -3,752.25% | |||
| Income Tax Expenses | 9.41% | 173.34% | |||
| Earnings from Continuing Operations | 91.69% | -33,897.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.92% | -33,897.73% | |||
| EBIT | 99.60% | -15,575.78% | |||
| EBITDA | 109.19% | -1,124.25% | |||
| EPS Basic | 25.96% | -34,237.29% | |||
| Normalized Basic EPS | 102.66% | -3,361.95% | |||
| EPS Diluted | 26.11% | -20,200.00% | |||
| Normalized Diluted EPS | 102.65% | -3,361.95% | |||
| Average Basic Shares Outstanding | -1.30% | -0.48% | |||
| Average Diluted Shares Outstanding | -0.98% | -0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
